Nat Med. 2011 Nov 7;17(11):1346-8. doi: 10.1038/nm.2501.
Although erythropoietin (Epo) is commonly used as a therapy for anemia, recent studies have suggested that Epo therapy is associated with adverse outcomes. A new study shows that polymeric IgA1 positively regulates erythropoiesis through binding to transferrin receptor 1 (Tfr1), suggesting new therapeutic routes for anemia (pages 1456–1465).
虽然促红细胞生成素 (Epo) 通常被用作治疗贫血的药物，但最近的研究表明，Epo 治疗与不良后果有关。一项新的研究表明，多聚免疫球蛋白 A1 通过与转铁蛋白受体 1 (Tfr1) 结合正向调节红细胞生成，为贫血的治疗提供了新的途径（第 1456-1465 页）。
